Premphase Side Effects Could Lead To Breast Cancer Lawsuits
Premphase | Lawsuits, Lawyers | Side Effects: Dementia, Alzheimer's Disease, Strokes, Blood Clots, Pulmonary Embolisms, Lupus, Breast Cancer
Premphase (Generic: Conjugated estrogens and Medroxyprogesterone acetate) has been linked to the following side effects: dementia, Alzheimer's disease, stroke, blood clots, pulmonary embolisms, lupus and breast cancer. Premphase is a hormone replacement therapy (HRT) prescribed for menopause symptoms.
Approximately 6 million women are taking Prempro to treat post-menopausal hot flashes and other menopause symptoms. However, a recent major study concludes that long-term use of Prempro is dangerous and significantly increases the risk of stroke, blood clots, heart attacks and breast cancer. These results were discovered in the nation's biggest hormone replacement study and were so alarming that the National Institute of Health (NIH) prematurely canceled the study, citing risk to the study's participants. As a result, the study is suggesting that many of the women who use Prempro and other estrogen and progestin combinations should quit taking the medications and talk to their doctors about alternatives.
The evidence is clear that Prempro and other estrogen progestin combinations can harm perfectly healthy women. Women taking Prempro have a 29% higher risk of heart attack, 41% higher risk of stroke and a 26% higher risk of breast cancer. Another study released on May 27, 2003 about the health risks of hormone replacement therapy concluded that the medications can double the risk of dementia and Alzheimer's disease.
Premphase, Premarin and Prempro are manufactured by Wyeth and accounted for about $890 million of the company's $13.9 billion in sales in 2001.
Legal Help For Victims Affected By Premphase
If you or a loved one took Premphase and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).